SAN

84.96

+0.38%↑

MRK1

120.5

+0.84%↑

SHL.DE

43.39

+1.97%↑

ARGX

769.8

-2.73%↓

PHIA

23.33

+2.73%↑

SAN

84.96

+0.38%↑

MRK1

120.5

+0.84%↑

SHL.DE

43.39

+1.97%↑

ARGX

769.8

-2.73%↓

PHIA

23.33

+2.73%↑

SAN

84.96

+0.38%↑

MRK1

120.5

+0.84%↑

SHL.DE

43.39

+1.97%↑

ARGX

769.8

-2.73%↓

PHIA

23.33

+2.73%↑

SAN

84.96

+0.38%↑

MRK1

120.5

+0.84%↑

SHL.DE

43.39

+1.97%↑

ARGX

769.8

-2.73%↓

PHIA

23.33

+2.73%↑

SAN

84.96

+0.38%↑

MRK1

120.5

+0.84%↑

SHL.DE

43.39

+1.97%↑

ARGX

769.8

-2.73%↓

PHIA

23.33

+2.73%↑

Kodu・Aktsiate loetelu・Nanobiotix

N
Nanobiotix

Suletud

18.36 -1.82

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

18.04

Max

18.44

Põhinäitajad
By Trading Economics
Sissetulek	41M -5.4M
Müük	48M 27M
Kasumimarginaal	-20.208
Töötajad	103
EBITDA	46M 1.1M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+25.82% upside

Turustatistika
By TradingEconomics
Turukapital	-49M 858M
Eelmine avamishind	20.18
Eelmine sulgemishind	18.36

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

2.975 / 3.015 Toetus ja vastupanu

Nanobiotix Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

7. dets 2025, 23:00 UTC

Omandamised, ülevõtmised, äriostud

Brookfield, GIC Agree $4.5 Billion Deal for Australia's National Storage -- Update

5. dets 2025, 21:08 UTC

Omandamised, ülevõtmised, äriostud

Meta Platforms Buys AI-Device Maker Limitless

5. dets 2025, 19:39 UTC

Suurimad hinnamuutused turgudel

Parsons' FAA Bid Loss Clouds Outlook After Rocky Year for Contractors

5. dets 2025, 19:17 UTC

Omandamised, ülevõtmised, äriostud

Constellation Energy Agrees to Divest Assets to Finalize Calpine Deal

7. dets 2025, 23:42 UTC

Market Talk

Nikkei May Rise on Weaker Yen -- Market Talk

7. dets 2025, 23:05 UTC

Market Talk

RBA Set to Remain 'Emphatically' On Hold, Westpac Says -- Market Talk

7. dets 2025, 22:18 UTC

Market Talk

RBA Set To Conclude Year With Hawkish Message -- Market Talk

6. dets 2025, 16:52 UTC

Omandamised, ülevõtmised, äriostud

As Netflix Swoops In to Buy Warner Bros., We Revisit the Studio's Long, Twisted Journey -- Barrons.com

6. dets 2025, 10:30 UTC

Omandamised, ülevõtmised, äriostud

Why Netflix Shareholders Aren't Thrilled to Acquire Warner Bros. -- Heard on the Street -- WSJ

6. dets 2025, 02:38 UTC

Omandamised, ülevõtmised, äriostud

How a Netflix-Warner Deal Would Change Everything in Hollywood -- Again -- WSJ

5. dets 2025, 21:59 UTC

Omandamised, ülevõtmised, äriostud

Netflix's Megadeal Will Need the Trump Administration's Blessing -- Update

5. dets 2025, 21:50 UTC

Market Talk

Tulu

Financial Services Roundup: Market Talk

5. dets 2025, 21:50 UTC

Omandamised, ülevõtmised, äriostud

The Netflix and Warner Bros. Deal Is Far From a Sure Thing -- Barrons.com

5. dets 2025, 21:36 UTC

Market Talk

Return of Shipping to Red Sea a Step Closer, Xeneta Says -- Market Talk

5. dets 2025, 21:35 UTC

Omandamised, ülevõtmised, äriostud

The Netflix-Warner Bros. Deal Has a Wildcard. How Paramount Could Still Win. -- Barrons.com

5. dets 2025, 21:26 UTC

Omandamised, ülevõtmised, äriostud

Warner Bros. Discovery and Netflix Enter Exclusive Deal Negotiations -- 7th Update

5. dets 2025, 21:12 UTC

Market Talk

Natural Gas Surge 9% This Week on Strong Flow of Exports -- Market Talk

5. dets 2025, 21:03 UTC

Market Talk

Tulu

Bank of Montreal Logs Solid Quarter, Though Some Unease Remains -- Market Talk

5. dets 2025, 21:01 UTC

Market Talk

Oil Caps Positive Week on Geopolitical Turmoil -- Market Talk

5. dets 2025, 20:43 UTC

Omandamised, ülevõtmised, äriostud

Limitless CEO Siroker: Will No Longer Sell Pendant to New Customers

5. dets 2025, 20:43 UTC

Omandamised, ülevõtmised, äriostud

Limitless CEO Siroker: Existing Pendant Customers to Be Supported for at Least Another Year

5. dets 2025, 20:42 UTC

Omandamised, ülevõtmised, äriostud

Limitless CEO Dan Siroker: Limitless Has Been Acquired by Meta >META

5. dets 2025, 20:01 UTC

Omandamised, ülevõtmised, äriostud

Netflix Landed a Big Deal. Now it Could Have a Big Fight. -- WSJ

5. dets 2025, 19:44 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5. dets 2025, 19:44 UTC

Market Talk

Canada Dollar Gains Nearly 1% on Jobs Data, Rate Outlook -- Market Talk

5. dets 2025, 19:39 UTC

Market Talk

Silver Climbs to a New Record High -- Market Talk

5. dets 2025, 19:31 UTC

Omandamised, ülevõtmised, äriostud

Netflix Stock Falls. Wall Street Is Worried About Warner Deal's High Price and Debt. -- Barrons.com

5. dets 2025, 18:30 UTC

Market Talk

Canada Jobless Rate Can Fall More Before Labor Slack Disappears -- Market Talk

5. dets 2025, 18:28 UTC

Omandamised, ülevõtmised, äriostud

Netflix Stock Falls. Wall Street Is Worried About Warner Deal's High Price and Debt. -- Barrons.com

5. dets 2025, 18:24 UTC

Omandamised, ülevõtmised, äriostud

AMC and IMAX Stocks Drop. Roku Rises. How the Netflix-Warner Bros. Deal Could Shake Up Entertainment. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Nanobiotix Prognoos

Hinnasiht

By TipRanks

25.82% tõus

12 kuu keskmine prognoos

Keskmine 23 EUR 25.82%

Kõrge 25 EUR

Madal 21 EUR

Põhineb 3 Wall Streeti analüütiku instrumendi Nanobiotix 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi Nanobiotix aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

2.975 / 3.015Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Nanobiotix

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.